Global Dalbavancin Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dalbavancin Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
Dalbavancin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dalbavancin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Skin Infection and Soft Tissue Infection are the major drivers for the industry.
Dabavan star is a new antibiotic developed by Durata, named Dalvance, which was approved by FDA to be marketed in the United States on May 23, 2014. It is used to treat complex acute bacterial skin and skin structure infections in adults. The drug is a second-generation glycopeptide antibiotic given intravenously.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dalbavancin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Roche
Pfizer
Abbvie
Johnson
Sanofi
Merck
Novartis
Gilead
GSK
Amgen
Hayao
Segment by Type
Intravenous Therapy
Oral Type
Skin Infection
Soft Tissue Infection
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Dalbavancin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Dalbavancin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Dalbavancin industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Dalbavancin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Dalbavancin introduction, etc. Dalbavancin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Dalbavancin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Dalbavancin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dalbavancin market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Skin Infection and Soft Tissue Infection are the major drivers for the industry.
Dabavan star is a new antibiotic developed by Durata, named Dalvance, which was approved by FDA to be marketed in the United States on May 23, 2014. It is used to treat complex acute bacterial skin and skin structure infections in adults. The drug is a second-generation glycopeptide antibiotic given intravenously.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dalbavancin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Roche
Pfizer
Abbvie
Johnson
Sanofi
Merck
Novartis
Gilead
GSK
Amgen
Hayao
Segment by Type
Intravenous Therapy
Oral Type
Segment by Application
Skin Infection
Soft Tissue Infection
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Dalbavancin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Dalbavancin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Dalbavancin industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Dalbavancin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Dalbavancin introduction, etc. Dalbavancin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Dalbavancin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.